Paediatric antiretroviral update

Gillian Sorour¹, Nosisa Sipambo¹, Moherndran Archary^{2

3}

Affiliations

¹ Department of Paediatrics and Child Health, University of the Witwatersrand, Johannesburg, South Africa.
² Discipline of Paediatrics and Child Health, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
³ Department of Paediatrics, King Edward VIII Hospital, Durban, South Africa.

Editorial

Gillian Sorour et al. South Afr J HIV Med. 2023.

. 2023 Jul 6;24(1):1506.

doi: 10.4102/sajhivmed.v24i1.1506. eCollection 2023.

Gillian Sorour¹, Nosisa Sipambo¹, Moherndran Archary^{2

3}

¹ Department of Paediatrics and Child Health, University of the Witwatersrand, Johannesburg, South Africa.
² Discipline of Paediatrics and Child Health, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
³ Department of Paediatrics, King Edward VIII Hospital, Durban, South Africa.

No abstract available

References

1. Archary M, Van Zyl R, Sipambo N, Sorour G. Optimised paediatric antiretroviral treatment to achieve the 95-95-95 goals. S Afr J HIV Med. 2021;22(1):1–4. 10.4102/sajhivmed.v22i1.1278 - DOI - PMC - PubMed
1. National Department of Health . 2023 ART clinical guidelines for the management of HIV in adults, pregnancy and breastfeeding, adolescents, children, infants and neonates. Pretoria: National Department of Health; 2023.
1. National Department of Health . 2019 ART clinical guidelines for the management of HIV in adults, pregnancy, adolescents, children, infants and neonates. Pretoria: National Department of Health; 2019.
1. Cevik M, Orkin C, Sax PE. Emergent resistance to dolutegravir among INSTI-naïve patients on first-line or second-line antiretroviral therapy: A review of published cases. Open Forum Infect Dis. 2020. Jun 2;7(6):ofaa202. 10.1093/ofid/ofaa202 - DOI - PMC - PubMed
1. Molina J-M, Clotet B, Van Lunzen J, et al. . Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2(4):e127–e136. 10.1016/S2352-3018(15)00027-2 - DOI - PubMed